Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SZN-8141 for Injection
SZN-8141 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SZN-8141 Single Ascending Dose Level 1 | EXPERIMENTAL | Participants will receive a single dose of SZN-8141 for Injection |
| SZN-8141 Single Ascending Dose Level 2 | EXPERIMENTAL | Participants will receive a single dose of SZN-8141 for Injection |
| SZN-8141 Single Ascending Dose Level 3 | EXPERIMENTAL | Participants will receive a single dose of SZN-8141 for Injection |
| Name | Type | Description |
|---|---|---|
| SZN-8141 for Injection | BIOLOGICAL | SZN-8141 for Injection is a humanized antibody formulated for IVT administration |
Inclusion Criteria: * Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity * Age ≥18 years and ≤90 years old * Documented diagnosis of diabetes mellitus (type 1 or 2), as defined by the American Di...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901, Aflibercept |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE3 | Aflibercept |
| Oculis Holding AG | OCS | 2 | PHASE3 | Dexamethasone, Vehicle |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-RGX-314 Dose 1, Steroid, Aflibercept |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | bevacizumab |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-150 IVT, Aflibercept IVT |
| Alvotech | ALVO | 1 | PHASE3 | AVT29, Eylea HD |
| Kiora Pharmaceuticals, Inc. | KPRX | 1 | PHASE2 | KIO-104 |
| REGENXBIO, Inc. | RGNX | 1 | PHASE2 | RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept |
| Ocugen Inc | OCGN | 1 | PHASE1 | OCU200 |
| Adverum Biotechnologies, Inc. | ADVM | 1 | - | ADVM-022 |